Literature DB >> 29786757

Copy number abnormality of acute lymphoblastic leukemia cell lines based on their genetic subtypes.

Chihiro Tomoyasu1,2, Toshihiko Imamura3, Toshihiro Tomii1, Mio Yano4, Daisuke Asai5, Hiroaki Goto6, Akira Shimada7, Masashi Sanada8, Shotaro Iwamoto9, Junko Takita10, Masayoshi Minegishi11, Takeshi Inukai12, Kanji Sugita12, Hajime Hosoi1.   

Abstract

In this study, we performed genetic analysis of 83 B cell precursor acute lymphoblastic leukemia (B-ALL) cell lines. First, we performed multiplex ligation-dependent probe amplification analysis to identify copy number abnormalities (CNAs) in eight genes associated with B-ALL according to genetic subtype. In Ph+ B-ALL cell lines, the frequencies of IKZF1, CDKN2A/2B, BTG1, and PAX5 deletion were significantly higher than those in Ph- B-ALL cell lines. The frequency of CDKN2A/2B deletion in KMT2A rearranged cell lines was significantly lower than that in non-KMT2A rearranged cell lines. These findings suggest that CNAs are correlated with genetic subtype in B-ALL cell lines. In addition, we determined that three B-other ALL cell lines had IKZF1 deletions (YCUB-5, KOPN49, and KOPN75); we therefore performed comprehensive genetic analysis of these cell lines. YCUB-5, KOPN49, and KOPN75 had P2RY8-CRLF2, IgH-CRLF2, and PAX5-ETV6 fusions, respectively. Moreover, targeted capture sequencing revealed that YCUB-5 had JAK2 R683I and KRAS G12D, and KOPN49 had JAK2 R683G and KRAS G13D mutations. These data may contribute to progress in the field of leukemia research.

Entities:  

Keywords:  Acute lymphoblastic leukemia cell line; BTG1; CDKN2A; CDKN2B; Copy number abnormality; IKZF1

Mesh:

Substances:

Year:  2018        PMID: 29786757     DOI: 10.1007/s12185-018-2474-7

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  32 in total

1.  The paired box domain gene PAX5 is fused to ETV6/TEL in an acute lymphoblastic leukemia case.

Authors:  G Cazzaniga; M Daniotti; S Tosi; G Giudici; A Aloisi; E Pogliani; L Kearney; A Biondi
Journal:  Cancer Res       Date:  2001-06-15       Impact factor: 12.701

Review 2.  The regulation of INK4/ARF in cancer and aging.

Authors:  William Y Kim; Norman E Sharpless
Journal:  Cell       Date:  2006-10-20       Impact factor: 41.582

3.  Establishment and characterization of "biphenotypic" acute leukemia cell lines with a variant Ph translocation t(9;22;10) (q34;q11;q22).

Authors:  T Ariyasu; Y Matsuo; A Harashima; S Nakamura; S Takaba; T Tsubota; K Orita
Journal:  Hum Cell       Date:  1998-03       Impact factor: 4.174

4.  Biallelic loss of CDKN2A is associated with poor response to treatment in pediatric acute lymphoblastic leukemia.

Authors:  Marcin Braun; Agata Pastorczak; Wojciech Fendler; Joanna Madzio; Bartlomiej Tomasik; Joanna Taha; Marta Bielska; Lukasz Sedek; Tomasz Szczepanski; Michal Matysiak; Katarzyna Derwich; Monika Lejman; Jerzy Kowalczyk; Bernarda Kazanowska; Wanda Badowska; Jan Styczynski; Nina Irga-Jaworska; Joanna Trelinska; Beata Zalewska-Szewczyk; Filip Pierlejewski; Iwona Wlodarska; Wojciech Młynarski
Journal:  Leuk Lymphoma       Date:  2016-10-18

5.  Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin: Possible clinical application of mTOR inhibitor.

Authors:  Chikara Hirase; Yasuhiro Maeda; Shunsuke Takai; Akihisa Kanamaru
Journal:  Leuk Res       Date:  2008-09-09       Impact factor: 3.156

6.  Mutations of the p53 and ras genes in childhood t(1;19)-acute lymphoblastic leukemia.

Authors:  M Kawamura; A Kikuchi; S Kobayashi; R Hanada; K Yamamoto; K Horibe; T Shikano; K Ueda; K Hayashi; T Sekiya
Journal:  Blood       Date:  1995-05-01       Impact factor: 22.113

7.  Genes commonly deleted in childhood B-cell precursor acute lymphoblastic leukemia: association with cytogenetics and clinical features.

Authors:  Claire J Schwab; Lucy Chilton; Heather Morrison; Lisa Jones; Halima Al-Shehhi; Amy Erhorn; Lisa J Russell; Anthony V Moorman; Christine J Harrison
Journal:  Haematologica       Date:  2013-03-18       Impact factor: 9.941

8.  KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation.

Authors:  Yukimasa Shiotsu; Hitoshi Kiyoi; Yuichi Ishikawa; Ryohei Tanizaki; Makiko Shimizu; Hiroshi Umehara; Kenichi Ishii; Yumiko Mori; Kazutaka Ozeki; Yosuke Minami; Akihiro Abe; Hiroshi Maeda; Tadakazu Akiyama; Yutaka Kanda; Yuko Sato; Shiro Akinaga; Tomoki Naoe
Journal:  Blood       Date:  2009-06-18       Impact factor: 22.113

9.  Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients.

Authors:  Blanca Scheijen; Judith M Boer; René Marke; Esther Tijchon; Dorette van Ingen Schenau; Esmé Waanders; Liesbeth van Emst; Laurens T van der Meer; Rob Pieters; Gabriele Escherich; Martin A Horstmann; Edwin Sonneveld; Nicola Venn; Rosemary Sutton; Luciano Dalla-Pozza; Roland P Kuiper; Peter M Hoogerbrugge; Monique L den Boer; Frank N van Leeuwen
Journal:  Haematologica       Date:  2016-12-15       Impact factor: 9.941

10.  IKZF1 deletion is associated with a poor outcome in pediatric B-cell precursor acute lymphoblastic leukemia in Japan.

Authors:  Daisuke Asai; Toshihiko Imamura; So-ichi Suenobu; Akiko Saito; Daiichiro Hasegawa; Takao Deguchi; Yoshiko Hashii; Kimikazu Matsumoto; Hirohide Kawasaki; Hiroki Hori; Akihiro Iguchi; Yoshiyuki Kosaka; Koji Kato; Keizo Horibe; Keiko Yumura-Yagi; Junichi Hara; Megumi Oda
Journal:  Cancer Med       Date:  2013-05-09       Impact factor: 4.452

View more
  4 in total

1.  Development of Potent and Selective Janus Kinase 2/3 Directing PG-PROTACs.

Authors:  Lisa J Alcock; Yunchao Chang; Jamie A Jarusiewicz; Marisa Actis; Stanley Nithianantham; Anand Mayasundari; Jaeki Min; Dylan Maxwell; Jeremy Hunt; Brandon Smart; Jun J Yang; Gisele Nishiguchi; Marcus Fischer; Charles G Mullighan; Zoran Rankovic
Journal:  ACS Med Chem Lett       Date:  2022-02-21       Impact factor: 4.345

2.  Aurora B kinase as a therapeutic target in acute lymphoblastic leukemia.

Authors:  Hiroaki Goto; Yuki Yoshino; Mieko Ito; Junichi Nagai; Tadashi Kumamoto; Takesi Inukai; Yukari Sakurai; Naoyuki Miyagawa; Dai Keino; Tomoko Yokosuka; Fuminori Iwasaki; Satoshi Hamanoue; Masae Shiomi; Shoko Goto
Journal:  Cancer Chemother Pharmacol       Date:  2020-03-06       Impact factor: 3.333

3.  Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia.

Authors:  Yunchao Chang; Jaeki Min; Jamie A Jarusiewicz; Marisa Actis; Shanshan Yu-Chen Bradford; Anand Mayasundari; Lei Yang; Divyabharathi Chepyala; Lisa J Alcock; Kathryn G Roberts; Stanley Nithianantham; Dylan Maxwell; Lauren Rowland; Randolph Larsen; Aman Seth; Hiroaki Goto; Toshihiko Imamura; Koshi Akahane; Baranda S Hansen; Shondra M Pruett-Miller; Elisabeth M Paietta; Mark R Litzow; Chunxu Qu; Jun J Yang; Marcus Fischer; Zoran Rankovic; Charles G Mullighan
Journal:  Blood       Date:  2021-12-09       Impact factor: 25.476

4.  The RS4;11 cell line as a model for leukaemia with t(4;11)(q21;q23): Revised characterisation of cytogenetic features.

Authors:  Denise Ragusa; Evgeny M Makarov; Oliver Britten; Daniela Moralli; Catherine M Green; Sabrina Tosi
Journal:  Cancer Rep (Hoboken)       Date:  2019-08-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.